U.S. market Closed. Opens in 11 hours 23 minutes

GRCL | Gracell Biotechnologies Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2022-12-312021-12-312020-12-312019-12-312018-12-31
RevenueN/A366.00KN/AN/AN/A
Cost of RevenueN/AN/AN/AN/AN/A
Gross ProfitN/A366.00KN/AN/AN/A
Operating Expenses624.66M463.94M214.40M146.58M62.50M
Selling, General & Admin139.27M137.04M45.57M27.36M10.26M
Research & Development485.39M326.90M168.83M119.22M52.24M
Other Operating Expenses8.16M9.06M4.70M1.43M276.00K
Operating Income-624.66M-463.57M-214.40M-146.58M-62.50M
Other Expenses / Income17.17M11.82M2.50M7.92M276.00K
Before Tax Income-607.49M-451.75M-211.90M-138.66M-60.79M
Income Tax Expenses22.00K14.13M-14.74M-6.49M1.71M
Net Income-607.51M-465.88M-197.16M-132.18M-60.79M
Interest Expenses6.74M5.06M2.15MN/AN/A
Basic Shares Outstanding107.49M65.77M65.56M19.81M19.81M
Diluted Shares Outstanding107.49M65.77M65.56M19.81M19.81M
EBITDA-592.58M-385.13M-206.83M-144.01M-57.80M
EBITDA Margin0.00%-105,225.96%0.00%0.00%0.00%
EBIT-600.75M-446.69M-209.75M-138.66M-59.08M
EBIT Margin0.00%-122,046.72%0.00%0.00%0.00%
Financial Year End2022-12-312021-12-312020-12-312019-12-312018-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙